It has been shown that in some cancers like cardiac (Eimre et al. 2008) and skeletal muscle sarcoma (Patra et al. 2008), neuroblastoma (Klepinin et al. 2014), colorectal cancer (Kaldma et al. 2014) and prostate cancer (Amamoto et al. 2016) MtCK is downregulated. This evidence concerns the gene CKMT2 and prostate carcinoma.